Prostate Cancer Daily

May 29, 2026

Videos

Peer-to-Peer Clinical Conversations

Practical Approaches to Genetic Testing in Metastatic Hormone-Sensitive Prostate Cancer - Emmanuel Antonarakis

Emmanuel Antonarakis

Emmanuel Antonarakis recommends germline and somatic testing for all metastatic prostate cancer patients.

PAM50 Intrinsic Subtyping and Salvage Therapy Decisions After Prostatectomy - Jonathan Tward

Jonathan Tward

Jonathan Tward presents data using PAM50 molecular classifier in 130 post-prostatectomy biochemical recurrence patients receiving salvage radiation.

Beyond the Abstracts

Stockholm3 versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - Beyond the Abstract

Management of High-Risk Prostate Cancer in Spain: Results from a National Patterns of Care Survey - Beyond the Abstract

Conference Coverage

AUA 2026: Neoadjuvant Apalutamide Therapy Enhances Potency Preservation Following Radical Prostatectomy by Downstaging the Disease in Men with High-Risk Prostate Cancer: Results of a Randomized Three-Arm Phase II Trial

AUA 2026: Uptake of Doublet and Triplet Therapy for Men with De Novo Metastatic Castration Sensitive Prostate Cancer. Population-Based Study

AUA 2026: Does Triplet Therapy Improve Survival in Metastatic Hormone-Sensitive Prostate Cancer? A Bayesian Individual Patient Data Reanalysis

AUA 2026: Long-Term Oncological Outcomes of Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-Risk Prostate Cancer: Phase 3 Randomized Controlled Trial

AUA 2026: Extended Follow-up Shows Accumulating Benefit for Patients Treated with CAN-2409 + Prodrug in Combination with Standard of Care EBRT in Men with Localized Prostate Cancer – an Update from a Randomized, Placebo-Controlled Phase 3 Clinical Trial

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Increasing and more consistent use of pre-biopsy MRI in prostate cancer diagnosis: insights from a population-based study in the Netherlands.

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.

Comparison of the Swedish and Finnish Centers in the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Comparative analysis of genitourinary toxicity following bladder outlet obstruction procedures in patients before versus after radiotherapy for localized prostate cancer: a retrospective cohort study using the TriNetX database.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC